EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Superior efficacy of combination antibiotic therapy versus monotherapy in a mouse model of Lyme disease

Yasir Alruwaili, Mary B Jacobs, Nicole R Hasenkampf, Amanda C Tardo, Celine E McDaniel, Monica E Embers

Frontiers in Microbiology · 21.11.2023 · 14

DOI: 10.3389/fmicb.2023.1293300 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 21.11.2023. Verfasst von Yasir Alruwaili und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka, Saudi Arabia. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lyme disease (LD) results from the most prevalent tick-borne infection in North America, with over 476,000 estimated cases annually. The disease is caused by Borrelia burgdorferi (Bb) sensu lato which transmits through the bite of Ixodid ticks. Most cases treated soon after infection are resolved by a short course of oral antibiotics. However, 10–20% of patients experience chronic symptoms because of delayed or incomplete treatment, a condition called Post-Treatment Lyme Disease (PTLD). Some Bb persists in PTLD patients after the initial course of antibiotics and an effective treatment to eradicate the persistent Bb is needed. Other organisms that cause persistent infections, such as M. tuberculosis , are cleared using a combination of therapies rather than monotherapy. A group of Food and Drug Administration (FDA)-approved drugs previously shown to be efficacious against Bb in vitro were used in monotherapy or in combination in mice infected with Bb . Different methods of detection were used to assess the efficacy of the treatments in the infected mice including culture, xenodiagnosis, and molecular techniques. None of the monotherapies eradicated persistent Bb . However, 4 dual combinations (doxycycline + ceftriaxone, dapsone + rifampicin, dapsone + clofazimine, doxycycline + cefotaxime) and 3 triple combinations (doxycycline + ceftriaxone+ carbomycin, doxycycline + cefotaxime+ loratadine, dapsone+ rifampicin+ clofazimine) eradicated persistent Bb infections. These results suggest that combination therapy should be investigated in preclinical studies for treating human Lyme disease.

Schlagwörter

Stichwörter der Autor:innen

Borrelia burgdorferiLyme diseaseantibioticcombinationefficacymouse

Autor:innen und Institutionen

  • Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka, Saudi Arabia.
  • Division of Immunology, Tulane National Primate Research Center, Tulane University, Covington, LA, United States.
  • Department of Tropical Medicine, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, United States.

Förderung

  • NIH HHS

Zitieren

APA

Alruwaili, Y., Jacobs, M. B., Hasenkampf, N. R., Tardo, A. C., McDaniel, C. E., & Embers, M. E. (2023). Superior efficacy of combination antibiotic therapy versus monotherapy in a mouse model of Lyme disease. Frontiers in Microbiology, 14. https://doi.org/10.3389/fmicb.2023.1293300

Vancouver

Alruwaili Y, Jacobs MB, Hasenkampf NR, Tardo AC, McDaniel CE, Embers ME. Superior efficacy of combination antibiotic therapy versus monotherapy in a mouse model of Lyme disease. Frontiers in Microbiology. 2023;14. doi:10.3389/fmicb.2023.1293300

BibTeX
@article{Alruwaili2023,
  author = {Alruwaili, Yasir and Jacobs, Mary B and Hasenkampf, Nicole R and Tardo, Amanda C and McDaniel, Celine E and Embers, Monica E},
  title = {Superior efficacy of combination antibiotic therapy versus monotherapy in a mouse model of Lyme disease},
  journal = {Frontiers in Microbiology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fmicb.2023.1293300}
}
Kostenlos starten →